急性细菌性皮肤和皮肤结构感染疾病市场按药物类型、感染类型、给药途径、分销管道和地区划分

2025 年全球急性细菌性皮肤和皮肤结构感染疾病市场规模估计为 40.734 亿美元，预计到 2032 年将达到 61.29 亿美元，2025 年至 2032 年的年复合成长率（CAGR）为 6.0%。

数字。 2025 年急性细菌性皮肤和皮肤结构感染疾病市场占有率（%）

急性细菌性皮肤和皮肤结构感染疾病(ABSSSI) 是指影响皮肤和周围组织和结构的常见细菌感染疾病，包括主要皮肤脓肿、蜂窝性组织炎组织炎以及感染性伤口和溃疡。引起 ABSSSI 的常见细菌包括金黄色葡萄球菌和化脓性链球菌。由于抗生素抗药性的增加以及肥胖、糖尿病和生活方式改变等风险因素的增加，全球 ABSSSI 发生率正在上升。

市场动态

全球老年人口和糖尿病等合併症的增加增加了 ABSSSI 的风险。根据国际糖尿病联盟的数据，2020年约有4.63亿20-79岁的成年人患有糖尿病，预计到2045年这一数字将上升到7亿以上。老年人也更容易受到皮肤和软组织感染疾病。快速的都市化和生活方式的改变损害了免疫健康，进一步增加了全球 ABSSSI 的疾病负担。然而，有关临床测试和药物核准的严格规定可能会阻碍市场的成长。新型抗菌药物的持续研发和先进创伤护理疗法的快速应用为市场提供了丰厚的机会。

研究的主要特点

• 本报告对全球急性细菌性皮肤和皮肤结构感染疾病市场进行了详细分析，并提供了预测期（2025-2032 年）的市场规模（百万美元）和年复合成长率（CAGR%），假设基准年为 2024 年。
• 它还强调了各个领域的潜在收益成长机会，并说明了该市场的引人注目的投资提案矩阵。
• 它还提供了对市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景以及主要企业采用的竞争策略的重要见解。
• 全球急性细菌性皮肤和皮肤结构感染疾病市场的主要企业根据公司亮点、产品系列、关键亮点、财务表现和策略等参数进行分析。
• 主要企业包括 Fresenius SE &Co.KGaA、辉瑞公司、Amneal Pharmaceuticals LLC、Intas Pharmaceuticals Ltd.、卡迪拉医疗保健有限公司、Glenmark Pharmaceuticals Ltd.、葛兰素史克公司、Sun Pharmaceutical Industries Ltd.、Aurobindo Pharmau.、艾伯维公司、Melevas Ltd. s, Inc. 等。
• 本报告的见解将使负责人和企业经营团队能够就未来产品发布、新兴趋势、市场扩张和行销策略做出明智的决策。
• 全球急性细菌性皮肤和皮肤结构感染疾病市场迎合了该行业的各种相关人员，例如投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
• 相关人员可以透过全球急性细菌性皮肤和皮肤结构感染市场分析中使用的各种策略矩阵来促进他们的决策。

目录

第一章 调查目的与前提条件

• 研究目标
• 先决条件
• 简称

第二章 市场展望

• 报告描述
  • 市场定义和范围
• 执行摘要
• 一致的机会图 (COM)

第三章市场动态、法规与趋势分析

• 市场动态
  • 驱动程式
  • 限制因素
  • 机会
• 影响分析
• 市场趋势
• 监管情景
• 製造商收益
• 采用非侵入式感测器技术
• 收购和合作场景
• 产品发布/核准
• 资金筹措和投资
• PEST分析
• 波特的分析

4. 全球急性细菌性皮肤和皮肤结构感染疾病市场-冠状病毒 (COVID-19) 大流行的影响

• 整体影响
• 政府倡议
• COVID-19 市场影响

5. 2020-2032 年全球急性细菌性皮肤和皮肤结构感染疾病市场（按药物类型划分）（百万美元）

• 介绍
• 口服和肠外抗生素
• 奥利万星
• 德拉沙星
• 万古霉素
• 其他的
• 外用抗生素
• 过氧化氢
• 夫西地酸
• 莫匹罗星
• 瑞他帕林

6. 2020-2032 年全球急性细菌性皮肤和皮肤结构感染疾病市场（按感染类型划分）（百万美元）

• 介绍
• 医院获得性 ABSSSI
• 社区收购 ABSSSI

7. 2020 年至 2032 年全球急性细菌性皮肤和皮肤结构感染疾病市场，依给药途径划分（百万美元）

• 介绍
• 口服
• 肠外
• 局部的

8. 2020-2032 年全球急性细菌性皮肤和皮肤结构感染疾病市场按分销管道划分（百万美元）

• 介绍
• 医院药房
• 零售药局
• 网路药局

9. 2020-2032 年全球急性细菌性皮肤和皮肤结构感染疾病市场（按地区划分）（百万美元）

• 介绍
• 北美洲
• 拉丁美洲
• 欧洲
• 亚太地区
• 中东
• 非洲

第十章 竞争格局

• 公司简介
  • Fresenius SE &Co. KGaA
  • Pfizer, Inc.
  • Amneal Pharmaceuticals LLC
  • Intas Pharmaceuticals Ltd.
  • Cadila Healthcare Ltd.
  • Glenmark Pharmaceuticals Ltd
  • GSK plc
  • Sun Pharmaceutical Industries Ltd.
  • Aurobindo Pharma Ltd.
  • AbbVie, Inc.
  • Melinta Therapeutics, Inc.
  • Accord Healthcare Ltd.
  • Merck &Co., Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Paratek Pharmaceuticals, Inc.

第 11 章 分析师建议

• 兴衰
• 一致的机会地图

第 12 章参考文献与调查方法

• 参考
• 调查方法

Global Acute Bacterial Skin And Skin Structure Infections Market is estimated to be valued at USD 4,073.4 Mn in 2025 and is expected to reach USD 6,129.0 Mn by 2032, growing at a compound annual growth rate (CAGR) of 6.0% from 2025 to 2032.

Figure. Acute Bacterial Skin And Skin Structure Infections Market Share (%), By Region 2025

Acute bacterial skin and skin structure infections (ABSSSI) refer to common bacterial infections that involve the skin and surrounding tissue or structures such as major cutaneous abscesses, cellulitis, and infected wounds or ulcers. Some of the common bacteria that cause ABSSSI include Staphylococcus aureus and Streptococcus pyogenes. With rising antibiotic resistance and increasing risk factors such as obesity, diabetes, and lifestyle changes, the global incidence of ABSSSI increases.

Market Dynamics:

Growing geriatric population worldwide coupled with rising prevalence of comorbidities such as diabetes increases the risk of ABSSSI. According to the International Diabetes Federation, approximately 463 million adults aged 20-79 years lived with diabetes in 2020, and this figure is projected to rise to over 700 million by 2045. The elderly are also more susceptible to skin and soft tissue infections. Rapid urbanization and changes in lifestyle that compromise immune health have further increased the ABSSSI disease burden globally. However, stringent regulations pertaining to clinical trials and drug approvals can hinder the market growth. Ongoing R&D for novel antibacterial medications and rapid adoption of advanced wound care therapies offers lucrative opportunities in the market.

Key Features of the Study:

• This report provides an in-depth analysis of the global acute bacterial skin and skin structure infections market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global acute bacterial skin and skin structure infections market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this includes Fresenius SE & Co. KGaA, Pfizer, Inc., Amneal Pharmaceuticals LLC, Intas Pharmaceuticals Ltd., Cadila Healthcare Ltd., Glenmark Pharmaceuticals Ltd, GSK plc, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., AbbVie, Inc., Melinta Therapeutics, Inc., Accord Healthcare Ltd., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Paratek Pharmaceuticals, Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• Global acute bacterial skin and skin structure infections market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global acute bacterial skin and skin structure infections market.

Detailed Segmentation-

• By Drug Type:
  • Oral & Parenteral Antibiotics
  • Oritavancin
  • Delafloxacin
  • Vancomycin
  • Others
  • Topical Antibiotics
  • Hydrogen Peroxide
  • Fusidic Acid
  • Mupirocin
  • Retapamulin
• By Infection Type:
  • Hospital Acquired ABSSSI
  • Community Acquired ABSSSI
• By Route of Administration:
  • Oral
  • Parenteral
  • Topical
• By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Fresenius SE & Co. KGaA
  • Pfizer, Inc.
  • Amneal Pharmaceuticals LLC
  • Intas Pharmaceuticals Ltd.
  • Cadila Healthcare Ltd.
  • Glenmark Pharmaceuticals Ltd
  • GSK plc
  • Sun Pharmaceutical Industries Ltd.
  • Aurobindo Pharma Ltd.
  • AbbVie, Inc.
  • Melinta Therapeutics, Inc.
  • Accord Healthcare Ltd.
  • Merck & Co., Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Paratek Pharmaceuticals, Inc.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug Type
  • Market Snapshot, By Infection Type
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Regulatory Scenario
• Manufacturer Revenue
• Adoption of Non-invasive Sensor Technologies
• Acquisitions and Partnerships Scenario
• Product Launches/Approvals
• Funding and Investments
• PEST Analysis
• Porter's Analysis

4. Global Acute Bacterial Skin and Skin Structure Infections Market- Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the Market

5. Global Acute Bacterial Skin and Skin Structure Infections Market, By Drug Type, 2020 - 2032, (USD Mn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Oral & Parenteral Antibiotics
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Oritavancin
• Delafloxacin
• Vancomycin
• Others
• Topical Antibiotics
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Hydrogen Peroxide
• Fusidic Acid
• Mupirocin
• Retapamulin

6. Global Acute Bacterial Skin and Skin Structure Infections Market, By Infection Type, 2020 - 2032, (USD Mn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Hospital Acquired ABSSSI
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Community Acquired ABSSSI
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

7. Global Acute Bacterial Skin and Skin Structure Infections Market, By Route of Administration, 2020 - 2032, (USD Mn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Oral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Parenteral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Topical
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

8. Global Acute Bacterial Skin and Skin Structure Infections Market, By Distribution Channel, 2020 - 2032, (USD Mn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

9. Global Acute Bacterial Skin and Skin Structure Infections Market, By Region, 2020 - 2032, (USD Mn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Region, 2020-2032
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Infection Type, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Infection Type, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Infection Type, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Infection Type, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Infection Type, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Infection Type, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD Mn)
    • North Africa
    • Central Africa
    • South Africa

10. Competitive Landscape

• Company Profiles
  • Fresenius SE & Co. KGaA
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Pfizer, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Amneal Pharmaceuticals LLC
  • Intas Pharmaceuticals Ltd.
  • Cadila Healthcare Ltd.
  • Glenmark Pharmaceuticals Ltd
  • GSK plc
  • Sun Pharmaceutical Industries Ltd.
  • Aurobindo Pharma Ltd.
  • AbbVie, Inc.
  • Melinta Therapeutics, Inc.
  • Accord Healthcare Ltd.
  • Merck & Co., Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Paratek Pharmaceuticals, Inc.

11. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

12. References and Research Methodology

• References
• Research Methodology
• About us and Sales Contact